Crossmark

1326 Precision oncology strategy for EVOLVE104, a differentiated T cell engager for the novel solid tumor target ULBP2/5/6

Crossref DOI link: https://doi.org/10.1136/jitc-2024-SITC2024.1326

Published Online: 2024-11-05

Published Print: 2024-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

Authors

Sergeeva, Oksana

Fearnley, Amber

Zeiger, Jennifer

Brown, Colleen

Ward, Antonio

Lai, Zengzu

Yuan, Changqing

Jin, Guixian

Sarkar, Mohosin

Tam, Eric M

Preyer, Martin

Ding, Yanhuai

Andrien, Bruce

Aimone, Mark

Meade, Agnes

Martomo, Stella

Fine, Jay S

Myers, Jeremy S
License Information

License valid from 2024-10-28